Nwaru Bright I, Dhami Sangeeta, Sheikh Aziz
Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Medical School Doorway 3, Teviot Place, Edinburgh, EH8 9AG UK.
Evidence Based Healthcare Ltd, Edinburgh, UK.
Curr Treat Options Allergy. 2017;4(3):312-319. doi: 10.1007/s40521-017-0136-2. Epub 2017 Jun 3.
Idiopathic anaphylaxis is a rare life-threatening disorder with symptoms similar to other forms of anaphylaxis. There is lack of a robust evidence base underpinning the treatment of anaphylaxis and even less so for idiopathic anaphylaxis. Much of the evidence therefore comes from relatively small case series and expert opinion. Idiopathic anaphylaxis is a diagnosis of exclusion, requiring a thorough history and careful diagnostic work-up investigating possible triggers and underlying predisposing factors. Key diagnostic tests include skin-prick testing, tests for specific-IgE, component-resolved diagnostics, and in some cases for allergen challenge tests. Other recognized causes of anaphylaxis, such as foods, medications, insect stings, latex, and exercise, should all be considered, as should differential diagnoses such as asthma. While the cause of idiopathic anaphylaxis remains unknown, prompt treatment with intramuscular epinephrine (adrenaline) administered into the anterolateral aspect of the thigh is associated with good prognosis. There may also be a role for H1-antihistamines and corticosteroids as second-line agents. Patients need to be carefully monitored for signs of deterioration and/or a possible protracted or biphasic reaction. Patients with frequent episodes of anaphylaxis (e.g., six or more episodes/year) should be considered for preventive therapy, which may include corticosteroids, H1- and H2-antihistamines, and, in some cases, mast cell stabilizers such as ketotifen. Alternative immune-suppressants (e.g., methotrexate) and anti-IgE may rarely also need to be considered. In many cases, the frequency of anaphylaxis declines such that regular use of corticosteroids can be discontinued after 9-12 months. Pediatric patients should be treated with similar regimens as adults, but with appropriate dose adjustments. Patients should carry their self-injectable epinephrine and other emergency medications at all times in order to deal with emergency situations.
特发性过敏反应是一种罕见的危及生命的疾病,其症状与其他形式的过敏反应相似。目前缺乏强有力的证据基础来支持过敏反应的治疗,对于特发性过敏反应的证据更是少之又少。因此,大部分证据来自相对较小的病例系列和专家意见。特发性过敏反应是一种排除性诊断,需要详细的病史和仔细的诊断检查,以调查可能的触发因素和潜在的易感因素。关键的诊断测试包括皮肤点刺试验、特异性IgE检测、组分分辨诊断,在某些情况下还包括过敏原激发试验。还应考虑其他公认的过敏反应原因,如食物、药物、昆虫叮咬、乳胶和运动,以及哮喘等鉴别诊断。虽然特发性过敏反应的病因尚不清楚,但在大腿前外侧注射肌肉注射肾上腺素(肾上腺素)进行及时治疗与良好的预后相关。H1抗组胺药和皮质类固醇作为二线药物可能也有作用。需要密切监测患者是否有病情恶化和/或可能的迁延或双相反应的迹象。对于频繁发生过敏反应的患者(例如,每年发作6次或更多次),应考虑进行预防性治疗,可能包括皮质类固醇、H1和H2抗组胺药,在某些情况下还包括肥大细胞稳定剂,如酮替芬。也可能很少需要考虑使用其他免疫抑制剂(如甲氨蝶呤)和抗IgE。在许多情况下,过敏反应的频率会下降,以至于9至12个月后可以停止定期使用皮质类固醇。儿科患者应采用与成人相似的治疗方案,但需适当调整剂量。患者应随时携带自行注射的肾上腺素和其他急救药物,以应对紧急情况。